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niversitätsklinikum Marburg, Marburg, Germany; §§Klinik für All-
, Viszeral-, Thorax-, Transplantations- und Kinderchirurgie des
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tätsklinikum Hamburg-Eppendorf, Hamburg, Germany; §§§Institut
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ww.annalsofsurgery.comBackground: PJ and PG are established methods for reconstruction in
pancreatoduodenectomy. Recent prospective trials suggest superiority of
the PG regarding perioperative complications.
Methods: A multicenter prospective randomized controlled trial comparing
PG with PJ was conducted involving 14 German high-volume academic
centers for pancreatic surgery. The primary endpoint was clinically relevant
postoperative pancreatic fistula. Secondary endpoints comprised periopera-
tive outcome and pancreatic function and quality of life measured at 6 and
12 months of follow-up.
Results: From May 2011 to December 2012, 440 patients were randomized,
and 320 were included in the intention-to-treat analysis. There was no signifi-
cant difference in the rate of grade B/C fistula after PG versus PJ (20% vs 22%,
P¼ 0.617). The overall incidence of grade B/C fistula was 21%, and the in-
hospital mortality was 6%. Multivariate analysis of the primary endpoint
disclosed soft pancreatic texture (odds ratio: 2.1, P¼ 0.016) as the only
independent risk factor. Compared with PJ, PG was associated with an increased
rate of grade A/B bleeding events, perioperative stroke, less enzyme supple-
mentation at 6 months, and improved results in some quality of life parameters.
Conclusions: The rate of grade B/C fistula after PG versus PJ was not
different. There were more postoperative bleeding events with PG. Perioper-
ative morbidity and mortality of pancreatoduodenectomy seem to be under-
estimated, even in the high-volume center setting.
Keywords: pancreatoduodenectomy, pancreatogastrostomy, pancreatojejuno-
stomy, postoperative pancreatic fistula, postoperative pancreatic function
(Ann Surg 2016;263:440–449)
T he first successful pancreatoduodenectomy was performed as a2-stage procedure by Walter Kausch in 1909.1 Later, Allen O.
Whipple popularized the procedure by a series of 37 pancreatoduo-
denectomies during his career.2 Because of high mortality, the
operation was nearly abandoned in the 1970 s.2 In the 1990 s, large
retrospective series from specialized centers around the world set a
benchmark for operative mortality of below 5%.2 Nevertheless,
morbidity remains substantial after pancreatoduodenectomy.3–10
The main contributing factor is postoperative pancreatic fistula
(POPF), involving leakage of pancreatic juice from the pancreatic
anastomosis, which can lead to severe secondary complications such
as intra-abdominal abscesses and erosion bleeding.9,11,12 Data
regarding the prevention of POPF by application of somatostatin
analogues have been controversial thus far,13,14 but a recenter Health, Inc. All rights reserved.
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reduces POPF rates.15 Numerous attempts at improving pancreatic
anastomosis techniques to lower POPF rates have been pro-
posed.2,16,17 The hypothesis of this trial dates back to Walter Kausch,
who discussed the possibility of anastomosis of the pancreatic
remnant to the jejunum (pancreatojejunostomy, PJ) or the stomach
(pancreatogastrostomy, PG) in his 1912 original publication of the
first successful pancreatoduodenectomy.1
Almost all retrospective studies suggest superiority of PG over
PJ in terms of reduced POPF and other complications.18 To date,
however, conflicting results have been reported from 8 prospective
randomized controlled trials (RCTs) published from 1995 to 201419–26
(see Supplemental Digital Content Table S1, available at http://links.
lww.com/SLA/A778): Only 3 RCTs22,24,25 have demonstrated a
reduced rate of POPF after PG, and 4 RCTs20,22,24,25 found advantages
of PG over PJ in terms of postoperative complications. Soft pancreatic
texturewas identified as a risk factor for POPF and other complications
in 4 RCTs.19,21,23,25 However, the available RCTs have some limita-
tions. With the exception of the recent Belgian multicenter RCT 24
including 329 patients, total case numbers of the RCTs are relatively
low (n¼ 90–151) and only 2 RCTs are multicenter trials. Definitions
of perioperative outcomes vary as early trials did not use the current
consensus definitions of specific complications in pancreatic surgery
established by the International Study Group for Pancreatic Surgery
(ISGPS). Although many technical variations of PG and PJ have been
reported,16,17 all 8 RCTs were restricted to specific subtypes of PG and
PJ. Only 2 RCTs with contradictory results report on postoperative
pancreatic function measured during follow-up of 3 to 12 months: the
Egyptian trial26 reports worse and the Spanish trial25 reports better
pancreatic function. None of the RCTs report on quality of life during
follow-up.
Here we present data collected at 14 high-volume centers for
pancreatic surgery in Germany from the currently largest multicenter
randomized trial comparing PG with PJ with respect to perioperative
complications and long-term pancreatic function and quality of life.
PATIENTS AND METHODS
Study Design, Hypothesis, and Inclusion Criteria
The RECOnstruction after PANCreatoduodenectomy Study
(RECOPANC) was designed as a randomized, controlled, observer-
and patient-blinded multicenter trial with 2 parallel treatment arms
(PG and PJ) (see Supplemental Digital Content, available at http://
links.lww.com/SLA/A774). The hypothesis was that the rate of
clinically relevant POPF is lower after PG. Inclusion criteria were
planned pancreatoduodenectomy at one of the participating aca-
demic centers and age more than 18 years. Exclusion criteria were
participation in interfering clinical trials and expected lack of com-
pliance. With the rationale to increase willingness of participating
surgeons to recruit patients and to achieve greater generalizability of
the results, we did not restrict PG or PJ to a special technique. Fourteen
German academic centers (RECOPANC Trial Group27) with a median
case load of 78 major pancreatic resections per year (range: 29–499,
figures for year 2012 from the Association of German University
Clinics, http://www.uniklinika.de) participated in the trial.
Primary Endpoint and Sample Size
POPF is defined by ISGPS as the occurrence of amylase
activity in abdominal drain fluid of 3 times the upper serum limit on
postoperative day 3 or later.28,29 In brief, grade A fistula is self-
limited and does not need specific treatment, grade B requires
medical or invasive interventional treatment, and grade C leads to
reoperation and/or severe secondary complications. The primary
endpoint chosen for this trial was clinically relevant POPF, that is, Copyright © 2015 Wolters Kluw
 2015 Wolters Kluwer Health, Inc. All rights reserved.ISGPS grade B or C, with the modification that application of
somatostatin analogues was not considered a criterion for grading.
The primary endpoint was assessed on postoperative day 3 at hospital
discharge and on postoperative day 30 to detect all POPFs.
Based on the prior assumption of a POPF B/C rate of 6% and
16% with PG and PJ, respectively, a¼ 5% and b¼ 20%, a sample
size of 153 per treatment arm (PG vs PJ) was calculated with the
2-sided x2 test. An adaptive interim analysis of the primary endpoint
according to Bauer and Koehne30 was planned after recruitment of
152 patients to allow for premature trial termination (with 1-sided
stopping boundaries of P< 0.0038) and sample size recalculation.
Secondary Endpoints and Follow-up
Secondary surgical endpoints were death, relaparotomy, com-
pletion pancreatectomy, anastomotic leak other than pancreatic fistula,
wound infection, delayed gastric emptying, postpancreatectomy hem-
orrhage according to the ISGPS definitions,31,32 intra-abdominal
abscess requiring invasive treatment, operation time (skin incision
to skin closure), and postoperative hospital stay. Further secondary
endpoints included septic shock, respiratory failure, deep venous
thrombosis, lung embolism, myocardial infarction, and stroke. Pan-
creatic endocrine and exocrine functions and quality of life were
evaluated in long-term follow-up at baseline, 6 and 12 months after
the operation by the validated European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)
C30 and the pancreatic cancer module PAN26.33,34
Randomization and Blinding
Center-based block randomization was performed by the
participating centers using a centralized Web-based tool (Random-
izer Software, Institute for Medical Informatics, Statistics and Docu-
mentation of the Medical University of Graz, www.randomizer.at)
with allocation concealment. To avoid a possible intraoperative
selection of low-risk patients,23 randomization was performed pre-
operatively. Obviously, the surgeons were not blinded concerning the
intervention. Therefore, blinded observers at the participating centers
assessed the primary endpoint. Patients were kept blinded regarding
the intervention and unblinded only in the case of emergencies
where necessary.
Ethical Approval, Safety, and Registration
The study protocol was approved by the local ethics commit-
tees of the participating centers and carried out according to the rules
of Good Clinical Practice and the Declaration of Helsinki.35 Written
informed consent was obtained from each patient. An independent
institution served as the Data Safety Monitoring Board and was
responsible for on-site clinical monitoring, source data verification,
and management of severe adverse event reports (Center for Clinical
Studies, Freiburg, Germany). The trial was assigned a Universal Trial
Number (UTN U1111-1117-9588) and registered in the German
Trials Register (DRKS 00000767) on March 23, 2011. The study
protocol was published in Trials.27
Statistical Analysis
The primary endpoint was analyzed according to the inten-
tion-to-treat principle (see Supplemental Digital Content, available at
http://links.lww.com/SLA/A775). A multivariate logistic regression
model adjusting a priori for age, center, surgeon volume/experience,
and pancreatic texture was applied to compare POPF rates in both
treatment groups. Missing values for the primary endpoint were
replaced by imputed case analysis according to Higgins et al.36
Exploratory analysis was planned for secondary endpoints. SAS
software 9.1 (SAS 9.1 software, SAS, Cary NC) and 2-sided tests
were used for all calculations.er Health, Inc. All rights reserved.
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Trial Flow
A total of 618 patients were screened and 440 patients were
randomized from May 31, 2011, through December 5, 2012. The
number of patients randomized per center is shown in Supplemental
Digital Content Fig. S1, available at http://links.lww.com/SLA/A776,
and ranged from 6 to 84, with 5 centers recruiting less than 20 patients
and 2 centers recruiting more than 50 patients. After the interim
analysis of the first 152 included patients, the Data Safety and
Monitoring Board advised continuation of the trial. A total of 120
randomized patients were excluded from the final analysis: 3 patients
were randomized by mistake (randomized but not eligible), 5 did not
undergo laparotomy, and 112 did not receive pancreatoduodenectomy
and were, therefore, excluded from further analysis. Fifteen patients
randomized to PG received PJ and 12 patients randomized to PG
received PJ because of the surgeon’s technical preference. Reasons
given for PJ instead of PG included technical problems with PG: short
pancreatic remnant (n¼ 9), difficult pancreatic remnant mobilization
(n¼ 2), and gastric ulcer (n¼ 1); reasons for PG instead of PJ were soft
pancreas with small duct (n¼ 11) and pancreas divisum (n¼ 1). In
total, 320 patients were included in the intention-to-treat analysis of the
primary endpoint: 149 patients randomized for PJ and 171 randomized
for PG. Ninety-six patients did not finish the whole 12-month follow-
up because of prior death (n¼ 75), loss to follow-up (n¼ 10), with-
drawal of consent (n¼ 5), and other reasons (n¼ 6) (Fig. 1).
Patient Baseline Characteristics and Operations
Patient baseline parameters are shown in Table 1. The treat-
ment groups were balanced in terms of age, sex, body mass index,
indications, symptoms, preoperative biliary drainage, comorbidities, Copyright © 2015 Wolters Kluw
FIGURE 1. Trial flow chart. ITT indicates intention to treat; PP, pe
442 | www.annalsofsurgery.comAmerican Society of Anesthesiologists (ASA) Classification, medi-
cation, and standard laboratory parameters. The treatment groups
were also comparable in terms of operation technique, surgeon
experience/volume, and blood loss/intraoperative transfusion require-
ment. In particular, the rates of soft pancreata (PG vs PJ, 59% vs
57%) and nondilated pancreatic ducts (PG vs PJ, 58% vs 55%),
which are indicators for increased risk of fistula formation,5,37–40
were not significantly different between the 2 groups (Table 1).
Supplemental Digital Content Table S2, available at http://
links.lww.com/SLA/A779, shows the technical varieties used for PG
and PJ at the trial centers. According to the ISGPS classification for
pancreatic anastomoses,16 the most commonly performed techniques
were nonstented duct-mucosa anastomosis (ISGPS type I-A-S0)
with 2 interrupted monofilament resorbable suture rows for PJ
and nonstented dunking PG (ISGPS type II-B-S0) anastomosis with
purse-string plus interrupted monofilament resorbable suture.
Primary Endpoint Analysis
The rate of clinically relevant POPF was 20% after PG and
22% after PJ in the control group (P¼ 0.62, 2-sided x2 test, Table 2).
In a multivariate logistic regression model (Table 2), including
anastomotic technique (PG vs PJ), age, center (north vs south),
pancreatic texture (soft vs hard) and surgeon volume (pancreatic
resections per year), and soft pancreatic texture was the only
significant factor affecting POPF B/C, with an odds ratio estimate
of 2.1 (P¼ 0.016) (Table 2).
As there were 12 patients allocated to PG receiving PJ instead
and 15 patients with PG instead of PJ, we also performed an as-
treated analysis of the primary endpoint (see Supplemental Digital
Content Table S3, available at http://links.lww.com/SLA/A780). The
results did not differ from those of the intention-to-treat analysis.er Health, Inc. All rights reserved.
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TABLE 1. Patients, Baseline Parameters, and Operations
PJ PG Total
Parameter N or Median % or Range N or Median % or Range N or Median % or Range P
Total 149 171 320 —
Baseline Data
Age, yr 66 29–87 68 35–86 68 29–87 0.787
Sex
Male 93 62% 95 56% 188 59% 0.214
Female 56 38% 67 44% 132 41%
BMI (kg/m2) 25 15–43 25 16–39 25 15–43 0.706
Chronic pancreatitis 14 9% 14 8% 28 9%
Pancreatic adenocarcinoma 98 66% 104 61% 202 63%
Ampullary adenocarcinoma 11 7% 10 6% 21 7%
Indications 0.695
CNP 4 3% 8 5% 12 4%
NET 2 1% 3 2% 5 2%
Other 20 13% 32 19% 52 16%
Weight loss 89 60% 97 57% 186 58% 0.587
Symptoms
Pain 79 53% 84 49% 163 51% 0.487
Jaundice 72 48% 88 52% 160 50% 0.575
Preop biliary drainage
ERD 60 40% 61 36% 121 38% 0.396
PTD 4 3% 7 4% 11 3% 0.488
History of acute pancreatitis 20 13% 17 10% 37 12% 0.331
Chronic pancreatitis 40 27% 45 26% 85 27% 0.915
Prior abdominal surgery 69 46% 80 47% 149 47% 0.932
Cardiac 58 39% 68 40% 126 39% 0.878
pulmonary 14 9% 19 11% 33 10% 0.615
Comorbidities
Renal 15 10% 15 9% 30 9% 0.692
Hepatic 9 6% 10 6% 19 6% 0.942
Ex-smoker 40 27% 33 19% 73 23% 0.074
Active smoker 44 30% 42 25% 86 27%
Ex-alcohol abuse 17 11% 19 11% 36 11% 0.673
Active alcohol abuse 16 11% 24 14% 40 13%
ASA
I 14 10% 18 11% 32 10%
II 81 56% 86 52% 167 53%
III 50 34% 61 37% 111 36% 0.881
IV 1 1% 2 1% 3 1%
NA 3 2% 4 2% 7 2%
Medication
Glucocorticoids 4 3% 3 2% 7 2% 0.570
Immunosuppressives 2 1% 1 1% 3 1% 0.483
Analgesics 29 20% 45 26% 74 23% 0.147
Somatostatin analog 2 1% 0 0% 2 1% 0.129
Neoadjuvant cx 4 3% 3 2% 7 2% 0.570
Neoadjuvant rx 2 1% 1 1% 3 1% 0.483
Laboratory
Amylase [U/L] 51 13–360 58 9–536 56 9–536 0.168
Creatinine (mmol/L) 61 15–328 62 37–519 62 156–519 0.581
Bilirubin (mmol/L) 12 3–598 15 2–371 14 2–598 0.951
C-reactive protein (mg/L) 6 0–111 6 0–177 6 0–177 0.618
Total protein (g/L) 70 44–558 71 55–85 70 44–558 0.442
CA 19–9 (U/mL) 42 1–11,000 48 1–4,491 47 1–11,000 0.503
Hemoglobin (mmol/L) 8 4–10 8 4–10 8 4–10 0.418
Leukocytes (1000/mL) 7 3–18 7 3–19 7 3–19 0.436
Thrombocytes (1000/mL) 260 95–569 270 37–625 268 37–625 0.926
Operations
Surgeon experience
<5 29 20% 24 14% 53 17%
5–10 50 34% 54 32% 104 33% 0.301
>10 69 47% 92 54% 161 51%
NA 1 1% 1 1% 2 1%
<10 13 9% 15 9% 28 9%
(Continued )
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TABLE 1. (Continued)
PJ PG Total
Parameter N or Median % or Range N or Median % or Range N or Median % or Range P
Surgeon volumey
10–25 43 29% 49 29% 92 29%
>25 92 62% 106 62% 198 62% 0.999
NA 1 1% 1 1% 2 1%
Technique
PPPD 121 81% 134 78% 255 80% 0.528
Classic Whipple 28 19% 37 22% 65 20%
NA 5 3% 11 6% 16 5%
LAD
Standard 106 71% 124 73% 230 72% 0.331
Extended 38 26% 36 21% 74 23%
Portal venous resection 30 20% 29 17% 59 18% 0.465
Additional organ resection 39 26% 39 23% 78 24% 0.484
Blood loss 500 0–4,800 500 0–3,500 500 0–4,800 0.581
Intraoperative red blood cell transfusion
No 132 89% 146 85% 278 87%
1 3 2% 6 4% 9 3% 0.708
2 8 5% 13 8% 21 7%
>2 6 6% 6 6% 12 12%
Pancreatic texture
Hard 62 43% 66 41% 128 42%
Soft 83 57% 95 59% 178 58% 0.755
NA 4 3% 10 6% 14 4%
MPD diameter
Normal (3 mm) 78 55% 94 58% 172 56%
Dilated (>3 mm) 64 45% 69 42% 133 44% 0.630
NA 7 5% 8 5% 15 5%
P values derived from 2-sided x
2
test and Student t test.
Years of pancreatic surgery.
yPancreatoduodenectomies per year.
ASA indicates American Society of Anesthesiologists; BMI, body mass index; CA, 19-9, Carbohydrate antigen 19-9; CNP, cystic neoplasm of the pancreas; cx, chemotherapy;
ERD, endoscopic retrograde drainage; LAD, lymphadenectomy; MPD, main pancreatic duct; NA, not assessed; NET, neuroendocrine tumor; PPPD, pylorus preserving
pancreatoduodenectomy; PTD, percutaneous transhepatic drainage; rx, radiotherapy.
Keck et al Annals of Surgery  Volume 263, Number 3, March 2016Assessment of Learning Effects
The odds ratio estimate for fistula rate in surgeons with less
than 10 pancreatoduodenectomies was 1.2 to 6.8 (95% confidence
interval) but did not reach the significance level (P¼ 0.064 in
multivariate analysis, see Table 2). Surgeons with less than 10
pancreatoduodenectomies per year had a higher fistula rate with
PJ (46%) than with PG (27%), and this effect was gradually lost with
increasing individual case load (see Supplemental Digital Content
Table S4, available at http://links.lww.com/SLA/A781); however,
these differences did not reach statistical significance. There was also
no significant center effect as to the preferred type of anastomosis in
the participating centers (see Supplemental Digital Content Table S4,
available at http://links.lww.com/SLA/A781).
Perioperative Secondary Endpoint Analysis
Operation time did not differ between PG and PJ. There were
no significant differences between PG and PJ with regard to the
frequency of surgical complications such as delayed gastric empty-
ing, intra-abdominal abscesses, relaparotomy, completion pancrea-
tectomy, anastomotic leaks, and surgical site infection. There was
also no difference in the incidence of systemic complications such as
septic shock, respiratory failure, deep vein thrombosis, lung embo-
lism, and myocardial infarction. There were more (n¼ 5) stroke
events in the PG group but none in the PJ group (P¼ 0.035) and
significantly more postpancreatectomy hemorrhage events in the PG
group (P¼ 0.023), the latter due to more grade A (5% vs 1%) and B
(9% vs 4%) hemorrhages. Stroke and grade A/B bleeding were not Copyright © 2015 Wolters Kluw
444 | www.annalsofsurgery.comassociated, however (P¼ 0.998). Perioperative in-house mortality in
the treatment groups (PG vs PJ, 6% vs 5%, P¼ 0.963) and 90-day
mortality (PG vs PJ, 10% vs 5%, P¼ 0.167) were not statistically
different. Postoperative hospital stay was equal with a median of
16 days (Table 3).
Survival During Follow-up
Overall survival curves are given in Supplemental Digital
Content Fig. S2, available at http://links.lww.com/SLA/A777. One-
year (365 days) Kaplan-Meier survival estimates (standard error)
were 77% 3% in PG and 76% 4% in PJ and thus comparable
(P¼ 0.675 in 2-sided log-rank test) (see Supplemental Digital Con-
tent Fig. S2, available at http://links.lww.com/SLA/A777).
Pancreatic Function and Long-term Follow-up
The percentage of patients receiving oral enzyme replacement
rose from 8% preoperatively to around 80% during 6- and 12-month
follow-up. Exploratory analysis also suggested a significantly
reduced rate of oral enzyme replacement therapy in patients with
PG at 6 months after the operation (PG vs PJ, 72% vs 89%,
P< 0.001). This difference did not persist at 12-month follow-up
because of a slightly decreasing percentage of PJ patients using oral
enzyme supplementation (PG vs PJ, 72% vs 81%, P¼ 0.11). How-
ever, simultaneously the rate of patients reporting steatorrhea in the
PJ group increased (from 17% at 6 months to 22% at 12 months),
suggesting now insufficient enzyme supplementation in some
patients. This was not the case with PG, where reported steatorrheaer Health, Inc. All rights reserved.
 2015 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 3. Perioperative Secondary Endpoint Analysis
PJ PG Total
Parameter N or Median % or Range N or Median % or Range N or Median % or Range P
Total 149 171 320 —
Operation time 337 165–565 332 165–600 332 165–600 0.706
DGE (delayed gastric emptying)
No 87 59% 107 63% 194 61%
Grade A 39 27% 44 26% 83 26%
Grade B 9 6% 14 8% 23 7% 0.301
Grade C 12 8% 6 4% 18 6%
Missing 2 0 2
PPH (postpancreatectomy hemorrhage)
No 132 89% 135 79% 167 83%
Grade A 1 1% 9 5% 10 3%
Grade B 6 4% 16 9% 22 7% 0.023
Grade C 10 7% 11 6% 21 7%
IA with IPC drainage 19 13% 18 11% 37 12%
IA with OP drainage 12 8% 15 9% 27 8% 0.814
Other surgical complications
Relaparotomy completion 27 18% 20 12% 47 15% 0.100
Pancreatectomy 9 6% 6 4% 15 5% 0.285
Hepaticoenterostomy leak 5 3% 3 2% 8 3% 0.480
Gastroenterostomy leak 3 2% 6 4% 9 3% 0.511
SSI 18 12% 20 12% 28 12% 1.000
Systemic complications
Septic shock 4 3% 6 4% 10 3% 0.672
Respiratory failure 8 6% 12 7% 20 7% 0.542
Deep vein thrombosis 1 1% 0 0% 1 0% 0.283
Lung embolism 2 1% 3 2% 5 2% 0.766
Myocardial infarction 1 1% 1 1% 2 1% 0.923
Stroke 0 0% 5 3% 5 2% 0.035
Missing 6 7 13 —
Postoperative hospital stay (d) 16 3–129 15 5–208 16 3–208 0.404
In-house mortalityy 8/148 5% 10/169 6% 18/317 6% 0.963
90-d mortalityz 7/143 5% 16/165 10% 23/308 7% 0.167
P values derived from 2-sided x
2
test, Student t test.
According to the International Study Group for Pancreatic Surgery (ISGPS) definition.
yMissing data (n¼ 3) excluded.
zCensored cases (n¼ 12) excluded.
DGE indicates delayed gastric emptying; IA, intra-abdominal abscess; IPC, interventional percutaneous; OP, operative; PPH, postpancreatectomy hemorrhage; SSI, surgical site
infection requiring invasive treatment.
TABLE 2. Primary Endpoint Analysis
Univariate Analysis
Total No/POPF A POPF B/C
Parameter n n (%) n (%) P
All patients 320 253 (79%) 67 (21%) —
PJ 149 116 (78%) 33 (22%) 0.617
PG 171 137 (80%) 34 (20%)
Multivariate Analysis
Parameter Odds Ratio Lower CI Upper CI P
PG vs PJ 0.864 0.495 1.507 0.607
Age, yr 0.988 0.966 1.011 0.318
Soft vs hard pancreatic texture 2.094 1.145 3.827 0.016
Center location (north vs south) 1.048 0.58 1.896 0.876
Surgeon volume 10–25 vs >25 PD/yr 1.578 0.822 3.029 0.863
Surgeon volume <10 vs >25 PD/yr 2.801 1.155 6.794 0.064
P values derived from 2-sided x
2
test (univariate) and binary logistic regression (multivariate).
CI indicates 95% confidence interval; PD, pancreatoduodenectomy; POPF, postoperative pancreatic fistula grade according to the International Study Group for Pancreatic Surgery
definition.
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day was comparable in both treatment groups.
The prevalence of diabetes mellitus rose only slightly after
pancreatoduodenectomy (from 25% at operation to 31% at 12-month
follow-up) and was comparable after PG and PJ. Among diabetic
patients, there was an increase of insulin dependence from around
50% to around 70% after pancreatoduodenectomy, whereas the
percentage of patients with dietary therapy dropped only from
23% preoperatively to 13% and 9% at 6 and 12 months, respectively.
There was no significant difference between both treatment arms
(Table 4).
Quality of Life and Long-term Follow-up
At the time of operation, EORTC QLQ-C30 and PAN26 scores
were balanced between the treatment groups except for the physical
functioning scale scores, which were higher in the PG group
(P¼ 0.002). The patients assigned the lowest scores to role function-
ing and body image. Other major reported problems were fatigue,
insomnia, pain, and digestive symptoms such as altered bowel habit.
At 6 and 12 months after the operation, the most severe impairments
were observed in role functioning, altered bowel habit, and fatigue.
On the contrary, appetite, nausea, and hepatic symptoms improved.
At 6 months, a reduced score on the financial problems scale could
be observed (P¼ 0.044) in PG compared with PJ, which persisted at
12-month follow-up. Furthermore, emotional and social functioning
scale scores were significantly better after PG than after PJ
(P¼ 0.039 and 0.019) (see Supplemental Digital Content Table
S5, available at http://links.lww.com/SLA/A782).DISCUSSION
We report the currently largest RCT to compare PG and PJ in
terms of POPF and perioperative complications and long-term out-
come including quality of life. Of note, this multicenter trial was
independently monitored. In contrast to previous RCTs, PG or PJ was
not restricted to a specific subtype. The results of this trial have
several implications for clinical practice. First, although it was
designed to confirm the hypothesis of a reduction of clinically
relevant POPF in patients with PG, the results show similar rates
of grade B/C POPF regardless of the reconstruction method with an
overall rate of 21%. This is higher than the reported range of 4% to
18% from large retrospective benchmark series (see Supplemental
Digital Content Table S1, available at http://links.lww.com/SLA/
A778). The previous RCTs report fistula rates between 12% and 24%
(see Supplemental Digital Content Table S1, available at http://
links.lww.com/SLA/A778). In comparison with the other RCTs,
RECOPANC included the oldest patients (average 68 years vs
56–67 years in other RCTs) with the highest body mass index
(average 25 vs 21–25 in other RCTs). Of note, RECOPANC is also
the first RCT to report independent monitoring. Taken together, the
observed POPF rate must be considered valid in view of an ageing
general population with increased operative risk.
Also, overall in-hospital mortality of 6% and the 90-day
mortality of 7% in this trial do not meet the usually cited 5%
benchmark for pancreatoduodenectomy. It is above the reported
range of 0.7% to 3.7% from current large-scale retrospective series
(see Supplemental Digital Content Table S1, available at http://
links.lww.com/SLA/A778), whereas some RCTs report comparable
perioperative mortality rates of 0% to 11% (see Supplemental Digital
Content Table S1, available at http://links.lww.com/SLA/A778). In
agreement with a current study,41 our data highlight the relevance of
90-day mortality figures in pancreatic surgery. It seems appropriate
to accept that clinically relevant fistula rates of 20% and perioper-
ative mortality of more than 5% mirror clinical reality even in high- Copyright © 2015 Wolters Kluw
 2015 Wolters Kluwer Health, Inc. All rights reserved.volume pancreatic surgery. A similar effect was observed in the distal
pancreatectomy trial, which reported a pancreatic fistula rate after
distal pancreatic resection more than twice as high as previously
reported in several retrospective series.42,43
Meta-analysis of the available RCTs19–26 incorporating data
from this trial suggests no significant reduction in POPF rates (odds
ratio: 0.66; 95% confidence interval: 0.43–1.01; P¼ 0.056) (see
Supplemental Digital Content Table S6, available at http://links.
lww.com/SLA/A783 for details). This stands in contrast to current
meta-analysis.44
In a multivariate analysis, the single most important factor
influencing POPF rates was the quality and texture of the organ. Soft
pancreatic texture, as judged intraoperatively by the surgeon, has
been demonstrated to bear a higher risk for secondary complications,
erosion bleeding, and mortality in previous studies.6,9,11,24,37,38,40 It
has been shown that subjective evaluation of the pancreatic hardness
and texture strongly correlates with the histopathological degree of
fibrosis.40 On the one hand, pancreatic cancer and chronic pancrea-
titis are usually associated with hardening of the whole organ
including the pancreatic remnant; on the other hand, prophylactic
surgery for benign lesions such as cystic neoplasms or small tumors
such as ampullary cancer is usually associated with soft pancreatic
tissue.9,19,40
As outlined, all participating clinics were high-volume aca-
demic centers for pancreatic surgery, and there was no statistically
significant center effect regarding POPF rate. Nevertheless, a high
odds ratio for POPF in the low-volume surgeons indicates that
besides center volume, individual surgeon volume is a relevant factor
influencing complication rates in pancreatoduodenectomy.
Furthermore, from our data, it might be speculated that PG
offers an easier-to-learn technique suited for less experienced sur-
geons, but this effect did not reach statistical significance. This
opinion has also been expressed by other authors of previous
RCTs19,20,24,26 on the basis of the assumption that it is technically
easier to achieve secure invagination of the pancreatic remnant with
PG, especially in case of a bulky soft pancreas. Reasons given for
conversion to PG instead of PJ (soft pancreas in 11 of 12 cases) in the
current trial may reflect this assumption. However, operation time
was not reduced with PG in the current trial, and only 2 previous
RCTs23,26 found a shorter operation time with PG.
The incidence of grade A and B postpancreatectomy hemor-
rhages was increased after PG. By ISGPS definition, grade A
bleeding has no therapeutic consequence, but grade B events require
conservative or even invasive therapy and may be sentinels of later
grade C hemorrhage. The feared life-threatening (grade C) bleeding
events were not increased with PG. These findings confirm previous
retrospective and prospective observations, which showed increased
bleeding events from PGs.23,45,46 Meticulous hemostatic measures at
the pancreatic cut surface are, therefore, advised. There was a higher
rate of perioperative stroke events in patients with PGs that were not
associated with the bleeding events, however. For lack of a rational
explanation, this might be interpreted as an artifact of exploratory
data analysis.
Our reported length of hospital stay (median, 16 days) is about
twice as long as that usually reported from high-volume North
American centers (see Supplemental Digital Content Table S1,
available at http://links.lww.com/SLA/A778). Our explanations are
that due to law-enforced universal health care insurance in Germany,
patients usually do not experience financial pressure to be discharged
early, and the common practice is to discharge patients home after
full recovery. Even in a fast-track surgery program applied to
major pancreatic resections in a German center,47 patients were
discharged at median on day 10, with a 30-day readmission rate
of only 3.5%, whereas readmission rates of 15% to 20% afterer Health, Inc. All rights reserved.
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States.48,49 In consequence, readmission has been highlighted as a
significant problem by American scientific studies and is financially
penalized in the United States but not in Germany.47–51
The results of long-term pancreatic function follow-up in the
current trial may be interpreted as suggestive of better exocrine
function in patients with PG. However, pancreatic function was not
measured directly but by means of the surrogate parameters oral
enzyme supplementation and steatorrhea, and the drawback of
exploratory data analysis must be kept in mind. Previous RCTs with
smaller case numbers have reported inconsistent outcomes.25,26 The
current study represents the largest prospective evaluation of this
issue and will be followed by a prospective long-term observation of
the included patients. Regarding the usually encountered opinion that
pancreatic function is worse after PG compared with PJ, our results
suggest that this is not the case.
Only one previous retrospective study compared quality of life
after pancreatoduodenectomy with PG and PJ and found no differ-
ence, but it was unbalanced with regard to the preoperative patient
status.52 Follow-up in the present trial did not reveal differences
between the treatment groups in most aspects covered by the EORTC
QLQ-C30/PAN26 questionnaires. On the contrary, the few detected
that differences are not large enough to be considered clinically
relevant. We also interpret these as an artifact of explorative analysis
of the many quality-of-life aspects. Our results, however, provide
valuable data to identify major problems that impair the quality of
life of patients before and after pancreatoduodenectomy: role func-
tioning, altered bowel habit, and fatigue.
CONCLUSIONS
In summary, this trial demonstrated several salient findings.
Reconstruction by PG, when not restricted to a specific subtype and
evaluated in a multicenter setting, did not reduce perioperative
complications. Soft pancreatic tissue quality remains the most
influential factor for POPF rate. PG may offer a technically less
demanding but safe anastomotic technique. However, a higher rate of
postoperative grade A/B hemorrhage was observed, advocating
increased awareness toward hemostatic measures with PG. The rate
of POPF remains substantial and is currently underestimated. Peri-
operative mortality can surpass the 5% margin even in the high-
volume academic pancreatic surgery setting. Both may be attributed
to extended indications for pancreatoduodenectomy in an ageing
population. Quality of life in pancreatoduodenectomy patients is
most severely impaired regarding role functioning and body image.
The operation seems to ameliorate gastrointestinal and hepatic
symptoms but does not improve fatigue and role functioning.
Long-term exocrine pancreatic function after PG does not seem to
be inferior to PJ.
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